My Top 10 Ideas As Of End of June 2024
Disclaimer: Not investment advice. Do your own research. For informational purposes only. I reserve the right to change positions after publishing as events change. Position rankings are accurate as of pre-market 6/26/2024 when writing was completed.
Hello everyone, I still can’t dedicate the amount of time I would like to writing and podcasts but I am sticking to at least one post a month updating my Top 10 positions. I still have more turnover than I would like but I am hoping these positions roughly remain my Top 10 positions going forward over the next 12-18 months but we will see!
Let’s go!
Top 10 Holdings, By Position Size
Evolus (EOLS)
Nurix (NRIX)
Edgewise (EWTX)
Corbus (CRBP)
Celcuity (CELC)
Insulet (PODD)
Cullinan (CGEM)
Perspective Therapeutics (CATX)
Elevation Oncology (ELEV)
ALX Oncology (ALXO)
Upcoming Catalysts
Evolus
Achievements in June: Filled for approval of filler line in U.S, Neurotoxin launch in Spain
2H 2024 Catalysts: Q2 Earnings Call (August), Q3 Earnings Call (November)
2025 Catalysts: U.S. Approval of Filler Line, E.U. Filler Launch, 2025 Earnings Calls
Nurix
Achievements in June: CLL Phase 1 Data (Exceptional data, btw!)
2H 2024 Catalysts: Phase 1 Updates in CLL, Dose Expansion Enrollment Updates
2025 Catalysts: Dose Expansion Data, CLL Regulatory Guidance, Pivotal Trial Initiation
Edgewise Therapeutics
Achievements in June: N/A
2H 2024 Catalysts: oHCM Phase 1b Data (Q3), BMD Phase 2 Data (Q4), DMD Phase 1b Data (Q4), Full Enrollment of BMD Phase 3 Trial
2025 Catalysts: oHCM Development Plan Guidance, Potential Accelerated Approval Filing in BMD pending FDA feedback and data quality, DMD Post-GeneTx Phase 2 Data
Corbus Pharmaceuticals
Achievements in June: ASCO Data Update from partner on Nectin-4 ADC
2H 2024 Catalysts: Novo INV-202 (Inversago asset) Direct Readthrough for CB1R Obesity Program, Complete U.S. Dose Escalation Enrollment for Nectin-4 ADC
2025 Catalysts: U.S Nectin-4 ADC Dose Escalation Data, Partner Nectin-4 Data Updates, U.S First Patient In To CB1R Program
Celcuity
Achievements in June: Announced plans to initiate a Phase 3 trial in 1L HR+/HER2- Advanced Breast Cancer
2H 2024 Catalysts: Pivotal Phase 3 Data in 2L HR+/HER2- PIK3CA WT
2025 Catalysts: Pivotal Phase 3 Data in 2L HR+/HER2- PIK3CA MT, Phase 1b/2 Data in mCRPC
Insulet
Achievements in June: Type 2 Diabetes pivotal data (incredible data), G7 (U.S) and Libre 2 (E.U) sensor support, Netherlands and France launch, iPhone app limited rollout
2H 2024 Catalysts: Type 2 DM regulatory submission, potential launches in Spain, Italy, Canada, Sweden
2025 Catalysts: U.S. Type 2 approval, Libre 3 sensor integration worldwide
Cullinan Therapeutics
Achievements in June: Initial Data from Phase 2b Study in Zipalertinib
2H 2024 Catalysts: Autoimmune Disease IND Approval in Q3, Readthrough from Amgen Inebilizumab (CD19 mAb) Myasthenia Gravis Data
2025 Catalysts: Initial Data in Autoimmune Disease, Full Zipalertinib Phase 2b Data and Possible Accelerated Approval Filing
Perspective Therapeutics
Achievements in June: NET Data from IST presented at Society of Nuclear Medicine Meeting
2H 2024 Catalysts: Phase 1/2a NET Company-Run Data and RP2D Assessment, Phase 1/2a Metastatic Melanoma Initial Data, FAP-a IND Filing
2025 Catalysts: NET Dose Expansion Data, Metastatic Melanoma Combination Data with ICI
Elevation Oncology
Achievements in June: Announced Gastric/GEJ combination study plans with Dostarlimab (1L) and Ramucirumab (2L)
2H 2024 Catalysts: Gastric/GEJ Cancer Initial Phase 1 Data, HER3-ADC Development Candidate Nomination
2025 Catalysts: Gastric/GEJ Dose Expansion Data
ALX Oncology
Achievements in June: Initial Padcev Combination Data presented at ASCO
2H 2024 Catalysts: Phase 2/Potential Pivotal 2L HER2+ Gastric Cancer Data, Two Phase 2 HNSCC Datasets, Enhertu Breast Cancer Combination Phase 1 Data
2025 Catalysts: Potential 2L HER2+ Accelerated Approval Filing Pending Positive Data, Urothelial Data Updates with Padcev, Breast Cancer Combination Updates with Enhertu and Zanidatamab, Multiple Myeloma Data with Sarclisa, Keytruda Combination HNSCC Regulatory Guidance Pending Positive Data
Sorry I know that doesn’t go into a lot of details if you aren’t familiar with the stories and the editing is slightly a mess but wanted to put it on record for my benefit and to spark research if you are interested in any of those areas.
Stocks that fell off the list are Fulcrum (still own it, #11 position, just sold more than half around $9 which worked out, might re-add those shares if it continues to fall but confidence is maybe slightly decreased before the huge binary readout due to the RNA data), Ovid (binary went bust, did not work out, lost 40%), Fibrogen (sold almost all of my shares on a big pop on a nothingburger PR about a Regeneron supply agreement, made 40% to balance out the OVID loss), BridgeBio (didn’t like the setup before Alynlam data, dodged a bullet there, it’s just too big to drive significant value in the near term but you could do much worse).
That’s it for this month, thanks for reading!
Matt